Actuate therapeutics obtains complete responses and provides update on clinical trial of elraglusib for the treatment of relapsed/refractory ewing sarcoma

Chicago and fort worth, texas, sept. 09, 2024 (globe newswire) -- – actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), provided an update on its phase 1/2 trial of elraglusib in relapsed/refractory ewing sarcoma (r/r ews).
ACTU Ratings Summary
ACTU Quant Ranking